Page last updated: 2024-08-21

alpha-aminopyridine and Neointima

alpha-aminopyridine has been researched along with Neointima in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Cheng, W; Fang, ZM; Feng, X; He, Y; Jiang, DS; Li, R; Luo, H; Wei, X; Yi, X; Zhang, Z; Zhao, F; Zhu, XH1
Chen, K; Gan, X; Li, S; Li, X; Pei, H; Qiu, C; Sun, X; Wang, Q; Yang, D; Yang, Y1
Bruemmer, D; Diebold, S; Endorf, EB; Findeisen, HM; Hess, K; Kahles, F; Lehrke, M; Makowska, A; Marx, J; Marx, N; Stöhr, R; Tilstam, PV1
Bot, I; Bot, M; de Vries, H; Foks, AC; Ijzerman, AP; Korporaal, SJ; Kuiper, J; Ter Borg, MN; van Berkel, TJ; van Santbrink, PJ; van Veldhoven, J1

Other Studies

4 other study(ies) available for alpha-aminopyridine and Neointima

ArticleYear
JIB-04, a histone demethylase Jumonji C domain inhibitor, regulates phenotypic switching of vascular smooth muscle cells.
    Clinical epigenetics, 2022, 08-13, Volume: 14, Issue:1

    Topics: Aminopyridines; Animals; Cell Movement; Cell Proliferation; Disease Models, Animal; DNA Methylation; Histone Demethylases; Histones; Hydrazones; Mice; Muscle, Smooth, Vascular; Neointima; Phenotype

2022
Wild-type p53-induced phosphatase 1 promotes vascular smooth muscle cell proliferation and neointima hyperplasia after vascular injury via p-adenosine 5'-monophosphate-activated protein kinase/mammalian target of rapamycin complex 1 pathway.
    Journal of hypertension, 2019, Volume: 37, Issue:11

    Topics: Aminopyridines; AMP-Activated Protein Kinases; Animals; Becaplermin; Carotid Artery, Common; Cell Proliferation; Dipeptides; Disease Models, Animal; Drug Evaluation, Preclinical; Hyperplasia; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Protein Phosphatase 2C; Tumor Suppressor Protein p53; Vascular System Injuries

2019
PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
    Journal of molecular and cellular cardiology, 2015, Volume: 81

    Topics: Aminopyridines; Animals; Benzamides; Cell Adhesion; Cell Line; Cell Proliferation; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Femoral Artery; Gene Expression Regulation; Guanine Nucleotide Exchange Factors; Histones; Humans; Mice; Monocytes; Myocytes, Smooth Muscle; Neointima; Phosphodiesterase 4 Inhibitors; Rats; Signal Transduction; Transcription Factor RelA; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Vascular System Injuries

2015
Adenosine A₂B receptor agonism inhibits neointimal lesion development after arterial injury in apolipoprotein E-deficient mice.
    Arteriosclerosis, thrombosis, and vascular biology, 2012, Volume: 32, Issue:9

    Topics: Adenosine A2 Receptor Agonists; Aminopyridines; Animals; Apolipoproteins E; Cardiovascular Agents; Carotid Artery Injuries; Carotid Artery, Common; Carotid Stenosis; Cell Adhesion; Cell Proliferation; CHO Cells; Collagen; Cricetinae; Cricetulus; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; HEK293 Cells; Humans; Mice; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Neutrophil Activation; Neutrophils; Platelet Activation; Receptor, Adenosine A2B; Time Factors; Transfection

2012